Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
179
resultados
Última actualización
31/10/2026 [08:09:00]
Resumen de: US20260335295A1
A compound represented by Formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof according to one aspect can be utilized as a preventive or therapeutic agent and the like for degenerative diseases, such as macular degeneration (AMD), cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), in which HTRA1 activity deficiency is a factor in the aggravation of the diseases, and can be utilized as an adjuvant for efficiently and accurately performing screening of an HTRA activity modulator without temperature changes or the addition of substrates.
Resumen de: AU2025256964A1
The invention relates to compositions comprising a synergistic combination of memantine and vitamin D, to the method for preparing same and to the use thereof in the prevention and treatment of neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: AU2025239704A1
This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.
Resumen de: US20260337275A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: AU2025254772A1
Provided herein are postbiotic compositions prepared using fermentation and herbal substrate compositions for the treatment or prevention of the disruption of the gut-brain axis. Such postbiotic compositions can be used to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Resumen de: WO2025134078A1
The present invention relates to the compounds of formula (I), or an isotopic form, a stereoisomer, or pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The present invention also relates to pharmaceutical compositions comprising such compounds, chemical processes of preparation of such compounds and use of such compounds in the treatment of psychiatric and/or neurological disorders.
Resumen de: WO2025134150A1
This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators These compounds disrupt the PD-1/PD-L1 checkpoint pathway and may also disrupt one or more related checkpoint pathways. These compounds are useful in treating, preventing or ameliorating disorders such as cancer or infections.
Resumen de: EP4830706A1
0001 The present invention relates to use of a novel compound for preventing, alleviating, or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: EP4831178A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type 1 diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Resumen de: WO2025131275A1
The present invention relates to pharmaceutical compositions and medicaments comprising the compound of formula (I); or a stereoisomer, tautomer, pharmaceutically usable solvate or salt thereof, and dosage regimens for the administration thereof to human patients.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: EP4830784A2
Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia. Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reelin, or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.
Resumen de: US20260325583A1
0000 Disclosed are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.
Resumen de: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260325464A1
The present invention discloses a composition comprising compounds of Formula I for use in modulating and maintaining water homeostasis in the brain by modulating the expression of aquaporins. More specifically, the invention discloses the use of Gingerenone A in the management of neurodegenerative disorders, specifically Alzheimer's disease and Parkinson's disease by modulating aquaporin expression.
Resumen de: AU2024434669A1
The present invention belongs to the technical field of biomedicine, and relates to a class of dexborneol or fenchyl alcohol ester derivatives of 2-hydroxynicotinic acid, and pharmaceutical uses thereof. The structural general formula of the derivatives is (1), R1 being selected from -H, -Cl, a hydrocarbon group having 1-8 carbon atoms, -CF3, -CF2H, -CN, -SCH3, -OH, -CHO, -CH2OH, -CH2NH2, -COOH, halogenated phenyl, or -NR4R5; R4, R5 are independently selected from -H or -CH3; R2 is selected from -H, an alkyl group having 1-6 carbon atoms, an acyl group having 2-7 carbon atoms, or a carbamoyl group; R 3 is selected from formula (a) or formula (b); X is selected from -CH= or -N=. The derivatives have good inflammation-inhibiting effects, and at high concentrations, they exhibit low cytotoxicity and are safer. The derivatives can be used for preparing a drug for treating inflammation and inflammation-related diseases such as stroke, neuropathic pain, depression and Alzheimer's disease.
Resumen de: US20260327271A1
Recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment are described. The fusion proteins may be administered to patients having a disease or a disorder with the intention of mitigating and/or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and/or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in amyotrophic lateral sclerosis (ALS) patients associated with the condition or disease. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, for example, by a decrease or elimination of symptoms associated with ALS, and/or by a decrease in the duration of such symptoms.
Resumen de: US20260325453A1
0000 Polydopamine-coated nanoparticles are presented as a novel composition for intracranial delivery, designed to absorb UV photons and mitigate neuroinflammation in brain tissue. These nanoparticles feature a core that includes materials such as silica, gold, iron oxide, or polymeric micelles and are encapsulated within a polydopamine shell. Additionally, biologically active agents can be incorporated to enhance neuroprotection. Methods are provided for treating neurodegenerative diseases (e.g., Parkinson's, Huntington's, ALS, Alzheimer's) or improving glioblastoma therapy by administering the polydopamine-coated nanoparticles directly to affected brain regions via intracerebral injection, intrathecal infusion, or convection-enhanced delivery. Furthermore, the polydopamine-coated nanoparticles hold potential for pharmaceutical applications in developing medicaments targeting neuroinflammation and UV photon absorption within the central nervous system.
Resumen de: WO2026220933A1
Provided is a pharmaceutical composition that has fewer side effects and that makes it possible to obtain an effect of preventing or treating Parkinson's disease A pharmaceutical composition for preventing or treating Parkinson's disease according to an embodiment of the present invention contains a nucleic acid that inhibits the expression of Rap1GAP.
Resumen de: WO2026222314A1
The disclosure is directed, in part, to methods of treating a patient suffering from a neurodegenerative disease, e.g., Parkinson's disease, comprising administering to the patient and effective amount of a TYK2 inhibitor. In some embodiments, the patient has elevated myxovirus resistance protein 1 (MX1) gene or protein expression.
Resumen de: WO2026220298A1
Provided for are prodrugs of doxycycline. The prodrugs may be advantageously administered for the treatment of disease, including neurological and neurodegenerative diseases or disorders. Doxycycline prodrugs may have reduced antibiotic activity compared to doxycycline for improved pharmacological properties. Also provided for are methods of treating neurodegenerative diseases such as Parkinson's disease or an alpha synucleinopathy with the doxycycline prodrugs and pharmaceutical compositions thereof.
Resumen de: US20260325548A1
A method of reducing neuroinflammation, tau accumulation, tau phosphorylation, and/or corticosterone secretion to treat or prevent Alzheimer's disease or related dementias, depression, and/or anxiety in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Glucocorticoid receptor antagonists such as mifepristone and nanodendriplexes comprising RNA interference agents targeting FKBP5, IFI16, or a combination thereof exhibit efficacy in reducing abnormal tau accumulation and neuroinflammation in Cov-2-infected patients to reduce neurological symptoms associated with infection.
Resumen de: US20260325670A1
0000 The invention provides a composition for delivering an active pharmaceutical ingredient (API) and/or active nutraceutical ingredient (ANI) to the basal ganglia of a subject in need thereof comprising a plurality of nanoparticles surface decorated with caffeine, wherein the nanoparticles comprising: at least one API or ANI, at least one emulsifier, at least one emulsifier stabilizer, at least one water miscible solvent, and at least one solid lipid matrix core; and a pharmaceutically or nutraceutically acceptable carrier. The invention further provides methods for delivering active ingredients to the to the basal ganglia of a subject in need thereof and methods for treating Parkinson's disease.
Resumen de: US20260325575A1
Provided is a use of borate derivatives in the treatment of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disease. More particularly, the development and administration of pharmaceutical formulations including at least one borate derivative is provided. The borate derivatives are one or a mixture of compounds sodium pentaborate pentahydrate (NaB; NaB5O8·5H2O) or sodium perborate tetrahydrate (SPT; NaBO3·4H2O).
Nº publicación: US20260327703A1 22/10/2026
Solicitante:
UNIVERSITA\u2019 DI TRENTO [IT]
ST SUPERIORE DI SANITA\u2019 [IT]
UNIV DEGLI STUDI DI ROMA \u201CLA SAPIENZA [IT]
UNIVERSITA\u2019 DI TRENTO
ISTITUTO SUPERIORE DI SANITA\u2019
UNIVERSIT\u00C1 DEGLI STUDI DI ROMA \u201CLA SAPIENZA\"
Resumen de: US20260327703A1
0000 The present invention relates to microRNAs for use in diagnostic methods for diagnosing and/or for distinguishing by diagnosis Alzheimer's disease (AD), Frontotemporal Dementia (FTD), and possibly other tauopathies, and/or for measuring therapeutic effect of a treatment of FTD or AD.
BOPI
Sede Electrónica
